Vaccines

David Walker discusses the threat of bioterrorism and the importance of basic research.

Emergent Biosolutions, has become a multinational biopharma company, despite working in some difficult therapeutic areas including biodefense.

A single vector vaccine has been developed that could offer protection against tularemia, anthrax, plague and melioidosis.

How can we prepare ourselves for the threats of emerging infectious disease?

Meet the companies and researchers protecting us from bioterrorists who plan to harness the destructive power of infectious diseases.

The lack of evidence available from pharma companies to guide care of pregnant women is ethically unacceptable.

A vaccine using mRNA demonstrates potential for broad influenza protection.

No dinosaurs were harmed in the making of this vaccine…

We must find ways to better help vaccine manufacturers to fight the flu – and this is why we developed a new challenge agent for H3N2.

Products are becoming increasingly complex and we need to get better at recognizing the strategies with the best advantages.